|
1
|
Lencioni R, Llovet JM, Han G, Tak WY, Yang
J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, et al: Sorafenib
or placebo plus TACE with doxorubicin-eluting beads for
intermediate stage HCC: The SPACE trial. J Hepatol. 64:1090–1098.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptortyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hsu FT, Liu YC, Chiang IT, Liu RS, Wang
HE, Lin WJ and Hwang JJ: Sorafenib increases efficacy of vorinostat
against human hepatocellular carcinoma through
transductioninhibition of vorinostat-induced ERK/NF-κB signaling.
Int J Oncol. 45:177–188. 2014.PubMed/NCBI
|
|
5
|
Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau
CW, Cheng AL and Chen KF: Sorafenib enhances radiation-induced
apoptosis in hepatocellular carcinoma by inhibiting STAT3. Int J
Radiat Oncol Biol Phys. 86:456–462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wörns MA, Schuchmann M, Düber C, Otto G,
Galle PR and Weinmann A: Sunitinib in patients with advanced
hepatocellular carcinoma after progression under sorafenib
treatment. Oncology. 79:85–92. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH,
Chen PJ and Cheng AL: Activation of phosphatidylinositol
3-kinase/Akt signaling pathway mediates acquired resistance to
sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther.
337:155–161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH,
Lin MW, Chen PJ and Chen KF: Dovitinib induces apoptosis and
overcomes sorafenib resistance in hepatocellular carcinoma through
SHP-1-mediated inhibition of STAT3. Mol Cancer Ther. 11:452–363.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu C, Lin LI, Cheng YC, Feng ZR, Shao YY,
Cheng AL and Ou DL: Cyclin E1 inhibition can overcome sorafenib
resistance in hepatocellular carcinoma cells through
Mcl-1suppression. Clin Cancer Res. 22:2555–2564. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guruvayoorappan C and Kuttan G: Effect of
amentoflavone on the inhibition of pulmonary metastasis induced by
B16F-10 melanoma cells in C57BL/6 mice. Integr Cancer Ther.
6:185–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen JH, Chen WL and Liu YC: Amentoflavone
induces anti-angiogenic and anti-metastatic effects through
suppression of NF-κB activation in MCF-7 cells. Anticancer Res.
35:6685–6693. 2015.PubMed/NCBI
|
|
13
|
Pei JS, Liu CC, Hsu YN, Lin LL, Wang SC,
Chung JG, Bau DT and Lin SS: Amentoflavone induces cell-cycle
arrest and apoptosis in MCF-7 human breast cancer cells via
mitochondria-dependent pathway. In Vivo. 26:963–970.
2012.PubMed/NCBI
|
|
14
|
Lee JS, Sul JY, Park JB, Lee MS, Cha EY,
Song IS, Kim JR and Chang ES: Fatty acid synthase inhibition by
amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human
breast cancer cells. Phytother Res. 27:713–720. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee S, Kim H, Kang JW, Kim JH, Lee DH, Kim
MS, Yang Y, Woo ER, Kim YM, Hong J and Yoon DY: The biflavonoid
amentoflavone induces apoptosis via suppressing E7 expression, cell
cycle arrest at sub-G1 phase, and mitochondria-emanated intrinsic
pathways in human cervical cancer cells. J Med Food. 14:808–816.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma CY, Ji WT, Chueh FS, Yang JS, Chen PY,
Yu CC and Chung JG: Butein inhibits the migration and invasion of
SK-HEP-1 human hepatocarcinoma cells through suppressing the ERK,
JNK, p38, and uPA signaling multiple pathways. J Agric Food Chem.
59:9032–9038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang
T, Pan S, Sun X and Xu L: Bufalin reverses resistance to sorafenib
by inhibiting Akt activation in hepatocellular carcinoma: The role
of endoplasmic reticulum stress. PLoS One. 10:e01384852015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang WH, Chiang IT, Ding K, Chung JG, Lin
WJ, Lin SS and Hwang JJ: Curcumin-induced apoptosis in human
hepatocellular carcinoma j5 cells: Critical role of
ca(+2)-dependent pathway. Evid Based Complement Alternat Med.
2012:5129072012.PubMed/NCBI
|
|
19
|
Huang SH, Wu LW, Huang AC, Yu CC, Lien JC,
Huang YP, Yang JS, Yang JH, Hsiao YP, Wood WG, et al: Benzyl
isothiocyanate (BITC) induces G2/M phase arrest and apoptosis in
human melanoma A375.S2 cells through reactive oxygen species (ROS)
and both mitochondria-dependent and death receptor-mediated
multiple signaling pathways. J Agric Food Chem. 60:665–675. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ting CY, Wang HE, Yu CC, Liu HC, Liu YC
and Chiang IT: Curcumin triggers DNA damage and inhibits expression
of DNA repair proteins in human lung cancer cells. Anticancer Res.
35:3867–3873. 2015.PubMed/NCBI
|
|
21
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Perciavalle RM and Opferman JT: Delving
deeper: MCL-1′s contributions to normal and cancer biology. Trends
Cell Biol. 23:22–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morciano G, Giorgi C, Balestra D, Marchi
S, Perrone D, Pinotti M and Pinton P: Mcl-1 involvement in
mitochondrial dynamics is associated with apoptotic cell death. Mol
Biol Cell. 27:20–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
